Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs

Scientifica

Volumn 2016, Issue , 2016, Pages

  Sharma, Mayank ^a   Sharma, Rajesh ^a   Jain, Dinesh Kumar ^b  

^a DEVI AHILYA UNIVERSITY   (India)

^b IPS Academy   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015226866     PISSN: None     EISSN: 2090908X     Source Type: Journal    
DOI: 10.1155/2016/8525679     Document Type: Review

References (98)

1. U.Agrawal, R. Sharma, M. Gupta, and S. P.Vyas, "Is nanotechnology a boon for oral drug delivery?" Drug Discovery Today, vol. 19, no. 10, pp. 1530-1546, 2014.
2. X.-Q.Wang and Q. Zhang, "PH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs," European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, no. 2, pp. 219-229, 2012.
3. H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou, "Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles," Journal of Controlled Release, vol. 133, no. 3, pp. 238-244, 2009.
4. P. Khadka, J. Ro, H. Kim et al., "Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability," Asian Journal of Pharmaceutical Sciences, vol. 9, no. 6, pp. 304-316, 2014.
5. T. Hetal, P. Bindesh, and T. Sneha, "A review on techniques for oral bioavailability enhancement of drugs," International Journal of Pharmaceutical Sciences Review and Research, vol. 4, no. 3, pp. 203-223, 2010.
6. A. Bernkop-Schnürch, "Nanocarrier systems for oral drug delivery: do we really need them?" European Journal of Pharmaceutical Sciences, vol. 49, no. 2, pp. 272-277, 2013.
7. L. Zhang, S.Wang,M. Zhang, and J. Sun, "Nanocarriers for oral drug delivery," Journal of Drug Targeting, vol. 21, no. 6, pp. 515-527, 2013.
8. V. Kumar, A. Sharma, A. Sharma, G. Joshi, and V. Dhillon, "Recent Advances In Ndds (Novel Drug Delivery System) for delivery of anti-hypertensive drugs," International Journal of Drug Development & Research, vol. 3, no. 1, pp. 252-259, 2011.
9. L. M. Prisant and W. J. Elliott, "Drug delivery systems for treatment of systemic hypertension," Clinical Pharmacokinetics, vol. 42, no. 11, pp. 931-940, 2003.
10. L. M. Prisant, B. Bottini, J. T. DiPiro, and A. A. Carr, "Novel drug-delivery systems for hypertension," The American Journal of Medicine, vol. 93, no. 2, pp. 45S-55S, 1992.
11. K. Delmar and H. Bianco-Peled, "Composite chitosan hydrogels for extended release of hydrophobic drugs," Carbohydrate Polymers, vol. 136, pp. 570-580, 2016.
12. H. Gupta, D. Bhandari, and A. Sharma, "Recent trends in oral drug delivery: a review," Recent Patents on Drug Delivery and Formulation, vol. 3, no. 2, pp. 162-173, 2009.
13. S. L. Patwekar and M. K. Baramade, "Controlled release approach to novelmultiparticulate drug delivery system," International Journal of Pharmacy and Pharmaceutical Sciences, vol. 4, no. 3, pp. 757-763, 2012.
14. N. Jain, R. Jain, N. Thakur et al., "Nanotechnology: a safe and effective drug delivery system," Asian Journal of Pharmaceutical and Clinical Research, vol. 3, no. 3, pp. 159-165, 2010.
15. R. Singh and J.W. Lillard Jr., "Nanoparticle-based targeted drug delivery," Experimental and Molecular Pathology, vol. 86, no. 3, pp. 215-223, 2009.
16. J. Safari and Z. Zarnegar, "Advanced drug delivery systems: nanotechnology of health design - a review," Journal of Saudi Chemical Society, vol. 18, no. 2, pp. 85-99, 2014.
17. S. Kalepu and V. Nekkanti, "Insoluble drug delivery strategies: review of recent advances and business prospects," Acta Pharmaceutica Sinica B, vol. 5, no. 5, pp. 442-453, 2015.
18. M. Rangasamy and K. G. Parthiban, "Recent advances in novel drug delivery systems," International Journal of Research in Ayurveda and Pharmacy, vol. 1, no. 2, pp. 316-326, 2010.
19. S. Abeer, "Future medicine: nanomedicine," Journal InternationalMedical Sciences Academy, vol. 25,no. 3, pp. 187-192, 2012.
20. A. Gupta and S. Sehrawat, "Bioavailability enhancement of poorly water soluble drugs: a review," International Journal of Pharmaceutics and Life Sciences, vol. 2, no. 3, pp. 640-650, 2011.
21. S. S. Suri, H. Fenniri, and B. Singh, "Nanotechnology-based drug delivery systems," Journal of Occupational Medicine and Toxicology, vol. 2, article 16, 2007.
22. J. Shaji and V. Bhatia, "Novel lipid carriers for oral delivery of lipophilic drugs," International Journal of Pharmaceutical Sciences Review and Research, vol. 15, no. 1, pp. 47-53, 2012.
23. P. Boisseau and B. Loubaton, "Nanomedicine, nanotechnology in medicine," Journal de Physique Archives, vol. 12, pp. 620-636, 2011.
24. L. Mei, Z. Zhang, L. Zhao et al., "Pharmaceutical nanotechnology for oral delivery of anticancer drugs," Advanced Drug Delivery Reviews, vol. 65, no. 6, pp. 880-890, 2013.
25. D. D. Kumar and A. K. Singh, "Dendrimers: a novel carrier system for drug delivery," Journal of Drug Delivery &Therapeutics, vol. 4, no. 5, pp. 1-6, 2014.
26. B. Gorain, H. Choudhury, A. Kundu et al., "Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats," ColloidsandSurfaces B: Biointerfaces, vol. 115, pp. 286-294, 2014.
27. S. R. Croy and G. S. Kwon, "Polymeric micelles for drug delivery," Current Pharmaceutical Design, vol. 12, no. 36, pp. 4669-4684, 2006.
28. W. Xu, P. Ling, and T. Zhang, "Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly watersoluble drugs," Journal of Drug Delivery, vol. 2013, Article ID 340315, 15 pages, 2013.
29. S. Tripathy and M. K. Das, "Dendrimers and their applications as novel drug delivery carriers," Journal of Applied Pharmaceutical Science, vol. 3, no. 9, pp. 142-149, 2013.
30. A. K. Gupta, D. K. Mishra, and S. C. Mahajan, "Preparation and in-vitro evaluation of self emulsifying drug delivery system of antihypertensive drug valsartan," International Journal of Pharmacy & Life Sciences, vol. 2, no. 3, pp. 633-639, 2011.
31. N. A. Ochekpe, P. O. Olorunfemi, and N. C. Ngwuluka, "Nanotechnology and drug delivery part 2: nanostructures for drug delivery," Tropical Journal of Pharmaceutical Research, vol. 8, no. 3, pp. 275-287, 2009.
32. M. F. Francis, M. Cristea, and F. M. Winnik, "Polymeric micelles for oral drug delivery: why and how," Pure and Applied Chemistry, vol. 76, no. 7-8, pp. 1321-1335, 2004.
33. V. P. Torchilin, "Targeted polymeric micelles for delivery of poorly soluble drugs," Cellular and Molecular Life Sciences, vol. 61, no. 19-20, pp. 2549-2559, 2004.
34. C. Raval, N. Joshi, J. Patel, and U. M. Upadhyay, "Enhanced oral bioavailability of olmesartan by using novel solid self emulsifying drug delivery system," International Journal of Advanced Pharmaceutics, vol. 2, no. 2, pp. 82-92, 2012.
35. P. Satturwar, M. N. Eddine, F. Ravenelle, and J.-C. Leroux, "pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil," European Journal of Pharmaceutics and Biopharmaceutics, vol. 65, no. 3, pp. 379-387, 2007.
36. B. P. Sahu and M. K. Das, "Nanosuspension for enhancement of oral bioavailability of felodipine," Applied Nanoscience, vol. 4, no. 2, pp. 189-197, 2014.
37. H. Ge, Y. Hu, X. Jiang et al., "Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(ϵ-caprolactone)-poly(ethylene oxide)-poly(ϵ-caprolactone) amphiphilic triblock copolymer micelles," Journal of Pharmaceutical Sciences, vol. 91, no. 6, pp. 1463-1473, 2002.
38. C. Bharti, U. Nagaich, A. Pal, and N. Gulati, "Mesoporous silica nanoparticles in target drug delivery system: a review," International Journal of Pharmaceutical Investigation, vol. 5, no. 3, pp. 124-133, 2015.
39. D. Thakar, P. Bharadia, andV. Pandya, "Enhancement of solubility of poorlywater soluble anti hypertensive drug by nanosizing approach," Journal of Pharmacy and Bioallied Sciences, vol. 4, pp. 40-41, 2012.
40. V. J.Mohanraj and Y. Chen, "Nanoparticles - a review," Tropical Journal of Pharmaceutical Research, vol. 5, no. 1, pp. 561-573, 2006.
41. P. Quan, D. Xia, H. Piao et al., "Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation," AAPS PharmSciTech, vol. 12, no. 4, pp. 1136-1143, 2011.
42. M. Yu, X. Jie, L. Xu et al., "Recent advances in dendrimer research for cardiovascular diseases," Biomacromolecules, vol. 16, no. 9, pp. 2588-2598, 2015.
43. J. M. Gutiérrez, C. González, A.Maestro, I. Solè, C. M. Pey, and J. Nolla, "Nano-emulsions: new applications and optimization of their preparation," Current Opinion in Colloid & Interface Science, vol. 13, no. 4, pp. 245-251, 2008.
44. I. F. Alexa, M. Ignat, R. F. Popovici, D. Timpu, and E. Popovici, "In vitro controlled release of antihypertensive drugs intercalated into unmodified SBA-15 and MgO modified SBA-15 matrices," International Journal of Pharmaceutics, vol. 436, no. 1-2, pp. 111-119, 2012.
45. I. I. Slowing, J. L. Vivero-Escoto, C.-W. Wu, and V. S.-Y. Lin, "Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers," Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1278-1288, 2008.
46. S. Mukherjee, S. Ray, and R. S. Thakur, "Solid lipid nanoparticles: a modern formulation approach in drug delivery system," IndianJournal of Pharmaceutical Sciences, vol. 71,no. 4, pp. 349-358, 2009.
47. R. H.Müller, K.Mäder, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art," European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161-177, 2000.
48. K. H. Ramteke, S. A. Joshi, and S. N. Dhole, "Solid lipid nanoparticle: a review," IOSR Journal of Pharmacy, vol. 2, no. 6, pp. 34-44, 2012.
49. V. K. Venishetty, R. Chede, R. Komuravelli, L. Adepu, R. Sistla, and P. V. Diwan, "Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration," Colloids and Surfaces B: Biointerfaces, vol. 95, pp. 1-9, 2012.
50. V. V. Kumar, D. Chandrasekar, S. Ramakrishna, V. Kishan, Y. M. Rao, and P. V. Diwan, "Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics," International Journal of Pharmaceutics, vol. 335, no. 1-2, pp. 167-175, 2007.
51. P. Ekambaram and A. Abdul Hasan Sathali, "Formulation and evaluation of solid lipid nanoparticles of ramipril," Journal of Young Pharmacists, vol. 3, no. 3, pp. 216-220, 2011.
52. B. Parmar, S.Mandal, K. C. Petkar, L.D. Patel, and K. K. Sawant, "Valsartan loaded solid lipid nanoparticles: development, characterization and in vitro and ex vivo evaluation," International Journal of Pharmaceutical Sciences and Nanotechnology, vol. 4, no. 3, pp. 1483-1490, 2011.
53. M. Kaur, "Dendrimers: synthesis, its dosage forms and advantage over linear polymers," Mintage Journal of Pharmaceutical & Medical Sciences, vol. 3, no. 3, pp. 15-19, 2014.
54. P. Kesharwani, K. Jain, and N. K. Jain, "Dendrimer as nanocarrier for drug delivery," Progress in Polymer Science, vol. 39, no. 2, pp. 268-307, 2014.
55. B. K. Nanjwade, H. M. Bechra, G. K. Derkar, F. V. Manvi, and V. K. Nanjwade, "Dendrimers: emerging polymers for drugdelivery systems," European Journal of Pharmaceutical Sciences, vol. 38, no. 3, pp. 185-196, 2009.
56. V. R. Babu, V.Mallikarjun, S. R. Nikhat, and G. Srikanth, "Dendrimers: a new carrier system for drug delivery," International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 1, pp. 1-10, 2010.
57. S. Svenson and A. S. Chauhan, "Dendrimers for enhanced drug solubilization," Nanomedicine, vol. 3, no. 5, pp. 679-702, 2008.
58. S. P. Gautam and A. Verma, "PAMAM dendrimers: novel polymeric nanoarchitectures for solubility enhancement of candesartan cilexetil," Pharmaceutical Sciences, vol. 1, pp. 1-4, 2012.
59. D. A. Sica, "Pharmacotherapy review: calcium channel blockers," Journal of Clinical Hypertension, vol. 8, no. 1, pp. 53-56, 2006.
60. A. D'Emanuele, R. Jevprasesphant, J. Penny, and D. Attwood, "The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability," Journal of Controlled Release, vol. 95, no. 3, pp. 447-453, 2004.
61. B.Devarakonda,N. Li, and M. M. deVilliers, "Effect of polyamidoamine (PAMAM)dendrimers on the in vitro release of waterinsoluble nifedipine from aqueous gels," AAPS PharmSciTech, vol. 6, no. 3, pp. E504-E512, 2005.
62. S. Parveen, R. Misra, and S. K. Sahoo, "Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 2, pp. 147-166, 2012.
63. J. Patel, A. Dhingani, K.Garala, M. Raval, andN. Sheth, "Design and development of solid nanoparticulate dosage forms of telmisartan for bioavailability enhancement by integration of experimental design and principal component analysis," Powder Technology, vol. 258, pp. 331-343, 2014.
64. D. Liu, S. Yu, Z. Zhu et al., "Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation," International Journal of Pharmaceutics, vol. 475, no. 1-2, pp. 496-503, 2014.
65. K. Thadkala, C. Sailu, and J. Aukunuru, "Formulation, optimization and evaluation of oral nanosuspension tablets of nebivolol hydrochloride for enhancement of dissoluton rate," Der Pharmacia Lettre, vol. 7, no. 3, pp. 71-84, 2015.
66. R. Rajalakshmi, T. Venkataramudu, R. A. Kumar, K. D. Sree, andM.D. Kiranmayi, "Design and characterization of valsartan nano suspension," International Journal of Pharmacotherapy, vol. 2, no. 2, pp. 70-81, 2012.
67. C. Detroja, S. Chavhan, and K. Sawant, "Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study," Scientia Pharmaceutica, vol. 79, no. 3, pp. 635-651, 2011.
68. C. Solans and I. Solé, "Nano-emulsions: formation by lowenergy methods," Current Opinion in Colloid & Interface Science, vol. 17, no. 5, pp. 246-254, 2012.
69. D. Ghai and V. R. Sinha, "Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the poorly water-soluble selective β1-adrenoreceptor blocker Talinolol," Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 8, no. 5, pp. 618-626, 2012.
70. J. Guan, N. Zhao, Y. Zhai, C. Chu, H. Chen, and T. Zhang, "Pharmacokinetic performance of the nitrendipine intravenous submicron emulsion in rats," Asian Journal of Pharmaceutical Sciences, vol. 9, no. 6, pp. 330-335, 2014.
71. P. S. Rajinikanth, N. W. Keat, and S. Garg, "Self-nanoemulsifying drug delivery systems of Valsartan: preparation and in-vitro characterization," International Journal of Drug Delivery, vol. 4, pp. 153-163, 2012.
72. S. R. Mudshinge, A. B. Deore, S. Patil, and C. M. Bhalgat, "Nanoparticles: emerging carriers for drug delivery," Saudi Pharmaceutical Journal, vol. 19, no. 3, pp. 129-141, 2011.
73. S. Bamrungsap, Z. Zhao, T. Chen et al., "Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system," Nanomedicine, vol. 7, no. 8, pp. 1253-1271, 2012.
74. W. H. De Jong and P. J. A. Borm, "Drug delivery and nanoparticles: applications and hazards," International Journal of Nanomedicine, vol. 3, no. 2, pp. 133-149, 2008.
75. A. Z. Wilczewska, K. Niemirowicz, K. H. Markiewicz, and H. Car, "Nanoparticles as drug delivery systems," Pharmacological Reports, vol. 64, no. 5, pp. 1020-1037, 2012.
76. J. P. Rao and K. E. Geckeler, "Polymer nanoparticles: preparation techniques and size-control parameters," Progress in Polymer Science, vol. 36, no. 7, pp. 887-913, 2011.
77. M. Bharathia, S. C. Prasad, R. L. Eswari et al., "Preparation and in vitro & in vivo characterization of valsartan loaded eudragit nanoparticles," Der Pharmacia Sinica, vol. 3, no. 5, pp. 516-525, 2012.
78. M. L.-L. Verger, L. Fluckiger, Y.-I. Kim, M. Hoffman, and P. Maincent, "Preparation and characterization of nanoparticles containing an antihypertensive agent," European Journal of Pharmaceutics and Biopharmaceutics, vol. 46, no. 2, pp. 137-143, 1998.
79. Y. Zhang, T. Jiang, Q. Zhang, and S. Wang, "Inclusion of telmisartan in mesocellular foam nanoparticles: drug loading and release property," European Journal of Pharmaceutics and Biopharmaceutics, vol. 76, no. 1, pp. 17-23, 2010.
80. U. Jana, A. K. Mohanty, P. K. Manna, and G. P. Mohanta, "Preparation and characterization of nebivolol nanoparticles using Eudragit RS100," Colloids and Surfaces B: Biointerfaces, vol. 113, pp. 269-275, 2014.
81. F. Li, A. Zhu, X. Song, and L. Ji, "Novel surfactant for preparation of poly(l-lactic acid) nanoparticleswith controllable release profile and cytocompatibility for drug delivery," Colloids and Surfaces B: Biointerfaces, vol. 115, pp. 377-383, 2014.
82. L. Kumar, M. S. Reddy, R. S. Managuli, and G. Pai, "Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles," Saudi Pharmaceutical Journal, vol. 23, no. 5, pp. 549-555, 2015.
83. Y. I. Kim, L. Fluckiger, M. Hoffman, I. Lartaud-Idjouadiene, J. Atkinson, and P. Maincent, "The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats," British Journal of Pharmacology, vol. 120, no. 3, pp. 399-404, 1997.
84. X. Zheng, T.Wang, H. Jiang et al., "Incorporation of Carvedilol into PAMAM-functionalized MWNTs as a sustained drug delivery system for enhanced dissolution and drug-loading capacity," Asian Journal of Pharmaceutical Sciences, vol. 8, no. 5, pp. 278-286, 2013.
85. B. ShengWong, S. L. Yoong, A. Jagusiak et al., "Carbon nanotubes for delivery of small molecule drugs," Advanced Drug Delivery Reviews, vol. 65, no. 15, pp. 1964-2015, 2013.
86. S. M. N. Simões, A. R. Figueiras, F. Veiga, A. Concheiro, and C. Alvarez-Lorenzo, "Polymeric micelles for oral drug administration enabling locoregional and systemic treatments," Expert Opinion on Drug Delivery, vol. 12, no. 2, pp. 297-318, 2015.
87. G. A. Husseini and W. G. Pitt, "Micelles and nanoparticles for ultrasonic drug and gene delivery," Advanced Drug Delivery Reviews, vol. 60, no. 10, pp. 1137-1152, 2008.
88. G. Arzani, A. Haeri, M. Daeihamed, H. Bakhtiari-Kaboutaraki, and S. Dadashzadeh, "Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge," International Journal of Nanomedicine, vol. 10, pp. 4797-4813, 2015.
89. V. B. Junyaprasert and B. Morakul, "Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs," Asian Journal of Pharmaceutical Sciences, vol. 10,no. 1, pp. 13-23, 2015.
90. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, and K. Amighi, "Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine," International Journal of Pharmaceutics, vol. 299, no. 1-2, pp. 167-177, 2005.
91. P. Quan, K. Shi, H. Piao et al., "A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability," International Journal of Pharmaceutics, vol. 430, no. 1-2, pp. 366-371, 2012.
92. Q. Fu, J. Sun, X. Ai et al., "Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption," International Journal of Pharmaceutics, vol. 448, no. 1, pp. 290-297, 2013.
93. A.Hildebrand, K. Beyer, R. Neubert, P. Garidel, and A. Blume, "Temperature dependence of the interaction of cholate and deoxycholate with fluid modelmembranes and their solubilization into mixed micelles," Colloids and Surfaces B: Biointerfaces, vol. 32, no. 4, pp. 335-351, 2003.
94. S. K. R. Bobbala and P. R.Veerareddy, "Formulation, evaluation, and pharmacokinetics of isradipine proliposomes for oral delivery," Journal of Liposome Research, vol. 22, no. 4, pp. 285-294, 2012.
95. B.-N. Ahn, S.-K. Kim, and C.-K. Shim, "Preparation and evaluation of proliposomes containing propranolol hydrochloride," Journal of Microencapsulation, vol. 12, no. 4, pp. 363-375, 1995.
96. V. Nekkanti and G. Betageri, "Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics," Drug Development and Industrial Pharmacy, vol. 41, no. 12, pp. 2077-2088, 2015.
97. Y. Zhang, J. Wang, X. Bai, T. Jiang, Q. Zhang, and S. Wang, "Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs," Molecular Pharmaceutics, vol. 9, no. 3, pp. 505-513, 2012.
98. Y. Hu, Z. Zhi, Q. Zhao et al., "3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol," Microporous and Mesoporous Materials, vol. 147, no. 1, pp. 94-101, 2012.